Literature DB >> 7662836

Discrete strategies of cancer post-treatment surveillance. Estimation and optimization problems.

A D Tsodikov1, B Asselain, A Fourque, T Hoang.   

Abstract

We consider the cancer post-treatment surveillance to be represented by a discrete observation process with a non-zero false-negative rate. Using a simple stochastic model of cancer recurrence derived within the random minima framework, we obtain parametric estimates of both the time-to-recurrence distribution and the probability of false-negative diagnosis. Then assuming the false-negative rate known, we give a nonparametric maximum likelihood estimator for the tumor latency time distribution. When designing an optimal strategy of post-treatment surveillance, we proceed from the minimum of the expected delay in detecting tumor recurrence as a pertinent criterion of optimality. To solve this problem we give a dynamic programming algorithm. We illustrate the methods by analyzing data on breast cancer recurrence.

Entities:  

Mesh:

Year:  1995        PMID: 7662836

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  5 in total

1.  Estimating Cure Rates From Survival Data: An Alternative to Two-Component Mixture Models.

Authors:  A D Tsodikov; J G Ibrahim; A Y Yakovlev
Journal:  J Am Stat Assoc       Date:  2003-12-01       Impact factor: 5.033

2.  Semiparametric time-to-event modeling in the presence of a latent progression event.

Authors:  John D Rice; Alex Tsodikov
Journal:  Biometrics       Date:  2016-08-24       Impact factor: 2.571

3.  Dynamic Optimal Strategy for Monitoring Disease Recurrence.

Authors:  Hong Li; Constantine Gatsonis
Journal:  Sci China Math       Date:  2012-08-01       Impact factor: 1.331

4.  Identifiability of the joint distribution of age and tumor size at detection in the presence of screening.

Authors:  Leonid Hanin; Andrei Yakovlev
Journal:  Math Biosci       Date:  2007-01-12       Impact factor: 2.144

5.  Cure models as a useful statistical tool for analyzing survival.

Authors:  Megan Othus; Bart Barlogie; Michael L Leblanc; John J Crowley
Journal:  Clin Cancer Res       Date:  2012-06-06       Impact factor: 12.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.